Navigation Links
Rigel Announces Fourth Quarter and Year End 2011 Financial Results
Date:3/6/2012

010.  In June 2011, Rigel completed an underwritten public offering in which it sold 18,745,000 shares of its common stock pursuant to an effective registration statement at a price to the public of $8.00 per share. Rigel received net proceeds of approximately $140.5 million, after deducting underwriting discounts and commissions and offering expenses. Rigel expects to end 2012 with cash, cash equivalents and available for sale securities in excess of $140.0 million, which is expected to be sufficient to fund operations into 2014.

"During the past year, a number of Rigel's R&D programs have made significant strides, and we now have a broad and deep lineup of potential product candidates in our primary therapeutic areas of immunology and muscle disorders," said James M. Gower, chairman and chief executive officer of Rigel. He added, "In addition to our lead product, fostamatinib, which is in Phase 3 clinical trials with our partner AZ, our pipeline now includes three wholly-owned products currently in clinical studies and a queue of others projected to start first in human studies in 2013."

Pipeline/Program Update

As of March 2012, Rigel has eight novel small molecule programs in clinical or preclinical development, including Rigel's partner, AZ's Phase 3 clinical trial program (OSKIRA) with fostamatinib in patients with RA.   AZ has recently announced that it expects to file for a new drug application for fostamatinib with the U.S. Food and Drug Administration in the second half of 2013.  Rigel's seven other potential new product programs are the focus of Rigel's research and development teams and include:

  • R343, an inhaled SYK inhibitor for allergic asthma.   Rigel resumed responsibility for this program following closure of Pfizer Inc.'s allergy and respiratory development programs in 2011. Based on its mechanism of action, this inhaled SYK inhibitor is expected to provide a new treatment paradigm for the
    '/>"/>

  • SOURCE Rigel Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Rigel Announces Participation at Two Investor Conferences
    2. Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
    3. Rigel to Present at Oppenheimer Annual Healthcare Conference
    4. Rigel Announces Third Quarter 2011 Financial Results
    5. Rigel to Present at Two Upcoming Investor Conferences
    6. Rigel to Present at Wells Fargo Securities Healthcare Conference
    7. Rigel to Present at Jefferies Global Healthcare Conference
    8. Rigel Announces Pricing of Public Offering of Common Stock
    9. Rigel Announces Proposed Public Offering of Common Stock
    10. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
    11. Rigel Announces First Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... & Renshaw 17 th Annual Global Investment Conference, ... York City .  Dr. Michael Berelowitz , ... September 9, 2015. Presentation Details: ...
    (Date:9/4/2015)... 4, 2015 Future Prospects for ... Allergic Rhinitis drugs - new study showing ... is the market for allergic rhinitis drugs heading? What ... ,s new report shows you potential revenues and other ... Our 326 page report provides 273 tables, charts, ...
    (Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Pharmacovigilance (London, UK ... offering. Understanding PhV today - the ... working in Drug safety. This course ... with pharmacovigilance. New entrants as well as experienced ...
    Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
    ... Reportlinker.com announces that a new ... its catalogue: Opioids ... of Oxycontin and High Incidence Of ... to Drive the Market ...
    ... BRUNSWICK, N.J., May 26, 2011 Johnson & Johnson ... for its Pharmaceuticals business at a meeting with the ... committee and pharmaceuticals segment will review how the business ... medical needs and outpace pharmaceutical market growth with an ...
    Cached Medicine Technology:Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 2Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 3Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 4Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 5Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 6Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 7Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 8Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 9Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 10Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 11Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 12Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 13Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 14Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 15Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 16Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 17Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market 18Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5
    (Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Mike Day, ... in 2007, will compete in the Ironman World Championships in Kona on October 10th. ... have incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore ...
    (Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
    (Date:9/4/2015)... , ... September 04, 2015 , ... ... Benker Residence in South Glastonbury, Connecticut, has been selected for the Residential Award ... significant energy efficiency and resiliency measures. Chosen from a highly competitive field of ...
    (Date:9/4/2015)... ... 2015 , ... EMED Jamaica Global Ltd. (EMED), Jamaica’s premier ... into a multi-year agreement with Health City Cayman Islands. , ( http://www.healthcitycaymanislands.com ) ... healthcare, Jamaican healthcare and Health City Cayman Islands to deliver high-quality, affordable healthcare ...
    (Date:9/3/2015)... ... 2015 , ... Allied Anesthesia is proud to announce a continuing partnership with ... exception. , St. Jude was recently named one of the nation’s top stroke centers ... of only 10 hospitals in the state to earn the distinction. , The ...
    Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
    ... or Relenza, according to CDC , TUESDAY, Sept. 8 ... which are effective in treating the H1N1 swine flu, should ... those at high risk for complications from the disease, U.S. ... with underlying health conditions, such as asthma or diabetes, as ...
    ... , OAKLAND, Calif., Sept. 8 (Nasdaq: ... on August 31, 2009, the Company received a NASDAQ Staff Deficiency ... Listing Rule 5550(a)(4). This rule requires the Company to maintain ... the NASDAQ Capital Market. Subsequently on September 4, 2009, the Company ...
    ... MOUNTAIN VIEW, Calif., Sept. 8 VIVUS, Inc. (Nasdaq: ... and commercialization of novel therapeutic products, plans to announce the results ... on September 9th prior to market open. The announcement will ... Eastern time. , , Conference Call Information ...
    ... AUSTIN, Texas, Sept. 8 Organix-South, a manufacturer of ... Council,s (ABC) Adopt-an-Herb program by adopting ... will provide ABC with financial support to ensure that summaries ... ( Azadirachta indica ) are made available within ABC,s HerbMedPro ...
    ... , Expanding facility will provide training ... the Highbridge area of the Bronx , , ... officially open the newest addition to the non-profit agency on September ... cutting ceremony at the facility. Located at 1438 Ogden Ave., ...
    ... , INDIANAPOLIS, Sept. 8 WellPoint, Inc. (NYSE: ... to present at the 2009 Morgan Stanley Global Healthcare Unplugged Conference ... All interested parties are invited to listen to the webcast ... selecting the "Investor Info" link. Following the presentation, a webcast replay ...
    Cached Medicine News:Health News:Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says 2Health News:Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says 3Health News:NASDAQ Stock Market Confirms WorldHeart's Compliance with NASDAQ Listing Rule 5550(a)(4) 2Health News:VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results 2Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 2Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 3Health News:Organix-South Adopts Neem Through the American Botanical Council's Adopt-an-Herb Program 4Health News:Highbridge Community Life Center Grand Opening and Ribbon Cutting Ceremony for New Health Careers/Education Facility in the Bronx 2Health News:WellPoint Announces Appearance at Upcoming Conference 2
    CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
    CCR Medical conventional laryngoscopes....
    CCR Medical conventional laryngoscopes....
    ... LMA™ Airway., ,Launched in 1988, this ... is now standard practice in general anesthesia. ... the LMA Classic™ is a safe hands ... ,The LMA Classic™ can be used for ...
    Medicine Products: